Kiniksa CEO exercises options and sells 48,565 shares

Kiniksa Pharmaceuticals International, plc Chairman and CEO Sanj K. Patel reported an exercise-and-sale transaction in Class A Ordinary Shares.

Accepted by SEC EDGAR 05/01/2026 - 04:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc Chairman and CEO Sanj K. Patel reported an exercise-and-sale transaction in Class A Ordinary Shares. He exercised share options to acquire 48,565 shares at $30.93 per share and then sold 48,565 shares in an open-market transaction at a weighted-average price of $54.02 per share.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated October 31, 2025. Following these direct transactions, his directly held Class A Ordinary Shares were reduced to zero, while separate indirect holdings remain in several family trusts.

Insider Trade Summary 10b5-1

Exercise and Sale: 48,565 shares ($1.12M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Patel Sanj K

Role CHAIRMAN & CEO

Sold 48,565 shs ($2.62M)

Approx. gross sale proceeds $2.62M

Approx. exercise cost $1.50M

Approx. pre-tax spread $1.12M

Type	Security	Shares	Price	Value
Exercise	Share Option	48,565	$0.00	$0.00
Exercise	Class A Ordinary Share	48,565	$30.93	$1.50M
Sale	Class A Ordinary Share	48,565	$54.02	$2.62M
holding	Class A Ordinary Share	--	--	--
holding	Class A Ordinary Share	--	--	--
holding	Class A Ordinary Share	--	--	--

Holdings After Transaction: Share Option — 0 contracts (Direct); Class A Ordinary Share — 0 shares (Direct); Class A Ordinary Share — 76,174 shares (Indirect, Held by The Patel Family Irrevocable Trust of 2025); Class A Ordinary Share — 109,795 shares (Indirect, Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016); Class A Ordinary Share — 51,794 shares (Indirect, Held by The Anglia 2013 Revocable Trust)

Footnotes (3)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.155. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. The option is fully vested and exercisable.

Key Figures

Shares sold: 48,565 shares Sale price: $54.02 per share Option exercise price: $30.93 per share +2 more

5 metrics

Shares sold 48,565 shares Open-market sale of Class A Ordinary Shares on May 1, 2026

Sale price $54.02 per share Weighted-average sale price, trades between $54.00 and $54.155

Option exercise price $30.93 per share Exercise price for 48,565 share options converted into Class A Ordinary Shares

Options exercised 48,565 options Share options exercised into Class A Ordinary Shares on May 1, 2026

Indirect trust holdings 51,794; 109,795; 76,174 shares Class A Ordinary Shares held through family trusts as indirect ownership

Key Terms

Rule 10b5-1 plan, weighted average sales price, share option, exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 plan regulatory

"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sales price financial

"The price reported in this column reflects a weighted average sales price"

share option financial

"Security title: Share Option with underlying Class A Ordinary Share"

exercise or conversion of derivative security financial

"Transaction code description: Exercise or conversion of derivative security"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sanj K

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	05/01/2026		M(1)		48,565	A	$30.93	48,565	D
Class A Ordinary Share	05/01/2026		S(1)		48,565	D	$54.02(2)	0	D
Class A Ordinary Share								76,174	I	Held by The Patel Family Irrevocable Trust of 2025
Class A Ordinary Share								109,795	I	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016
Class A Ordinary Share								51,794	I	Held by The Anglia 2013 Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$30.93	05/01/2026		M(1)			48,565	(3)	09/19/2028	Class A Ordinary Share	48,565	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.155. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)